专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20110090374A1 SUB-FRAME TAPERED RESET 有权
标题翻译：子框复位
公开(公告)号：US20110090374A1
公开(公告)日：2011-04-21
申请号：US12582316
申请日：2009-10-20
申请人： Ying Huang , Giuseppe Rossi , Lester Joseph Kozlowski , Laurent Blanquart , Qianjiang Mao , Gregory Chow
发明人： Ying Huang , Giuseppe Rossi , Lester Joseph Kozlowski , Laurent Blanquart , Qianjiang Mao , Gregory Chow
IPC分类号： H04N5/217 , H04N5/335
CPC分类号： H04N5/363 , H04N5/343 , H04N5/3532 , H04N5/374 , H04N5/3765
摘要： Systems and methods are provided that facilitate employing a plurality of independent reset buses for a column of pixels in a pixel array of a CMOS sensor imager. Utilization of the plurality of independent reset buses for the column of pixels can enable independent reset to be effectuated when employing sub-frame integration. For example, rows to be read and reset during a given readout time interval can be selected based upon one or more criteria. Further, each of the rows selected during the given readout time interval can be associated with a respective distinct reset bus. By leveraging the plurality of independent reset buses, uniformity in pixel operation can be maintained whether operating in full frame integration mode or sub-frame integration mode. Thus, noise resultant from changing between integration modes can be mitigated by using the plurality of independent reset buses.
摘要翻译：提供了系统和方法，其便于对CMOS传感器成像器的像素阵列中的像素列采用多个独立的复位总线。对于像素列，多个独立复位总线的利用可以使得在采用子帧集成时能够实现独立的复位。例如，可以基于一个或多个标准来选择在给定的读出时间间隔期间要读取和复位的行。此外，在给定读出时间间隔期间选择的每行都可以与相应的不同的复位总线相关联。通过利用多个独立的复位总线，无论是在全帧集成模式还是子帧集成模式下操作，都可以保持像素操作的均匀性。因此，可以通过使用多个独立复位总线来减轻由积分模式之间变化引起的噪声。

52. 发明申请

US20100292203A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS 有权
公开(公告)号：US20100292203A1
公开(公告)日：2010-11-18
申请号：US12693874
申请日：2010-01-26
申请人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey O. Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert D. Mazzola , John P. Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Xiaoxiang Liu , Dawit Tadesse , Ying Huang , Guoqing Li , Jianping Pan
发明人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey O. Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert D. Mazzola , John P. Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Xiaoxiang Liu , Dawit Tadesse , Ying Huang , Guoqing Li , Jianping Pan
IPC分类号： A61K31/505 , C07D239/22 , A61K31/55 , A61K31/397
CPC分类号： C07D233/88 , A61K31/4168 , A61K31/4178 , C07D239/22 , C07D401/06 , C07D401/10 , C07D403/06 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/10 , C07D417/14 , C07D495/10
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

53. 发明授权

US07803802B2 Substituted amide beta secretase inhibitors 有权
标题翻译：取代的酰胺β分泌酶抑制剂
公开(公告)号：US07803802B2
公开(公告)日：2010-09-28
申请号：US11185419
申请日：2005-07-20
申请人： Ying Huang , Guoqing Li , Andrew W Stamford
发明人： Ying Huang , Guoqing Li , Andrew W Stamford
IPC分类号： A61K31/497 , C07D241/02
CPC分类号： C07D401/12 , C07D241/04 , C07D241/08 , C07D401/10 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula I and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula I, HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.
摘要翻译：公开了下式的新化合物或其药学上可接受的盐或溶剂化物，其中R1，R2，R3，R4和X如说明书中所定义。还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。还公开了治疗认知或神经退行性疾病的方法，包括向需要这种治疗的患者施用至少一种式I化合物和至少一种选自除了那些的那些之外的其他化合物式I，HMG-CoA还原酶抑制剂，γ-分泌酶抑制剂，非甾体抗炎剂，N-甲基-D-天冬氨酸受体拮抗剂，胆碱酯酶抑制剂和抗淀粉样蛋白抗体。

54. 发明申请

US20100152138A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT 有权
标题翻译：具有苯甲酸替代物的循环胺BACE-1抑制剂
公开(公告)号：US20100152138A1
公开(公告)日：2010-06-17
申请号：US12641952
申请日：2009-12-18
申请人： Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
发明人： Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
IPC分类号： A61K31/4015 , C07D207/12 , C07D217/24 , C07D413/12 , C07D243/08 , A61K31/47 , A61K31/675 , A61K31/397 , A61K31/5377 , A61K31/551 , A61P25/28
CPC分类号： C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要： Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification.Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译：公开了下式的化合物或其药学上可接受的盐或溶剂化物，其中R1是R是-C（O）-N（R27）（R28），或其余的变量如说明书中所定义。还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。还公开了治疗认知或神经变性疾病的药物组合物和方法，其包含式I化合物与除式I以外的分泌抑制剂抑制剂，HMG-CoA还原酶抑制剂，γ-分泌酶抑制剂，非 - 甾族抗炎药，N-甲基-D-天冬氨酸受体拮抗剂，胆碱酯酶抑制剂或抗淀粉样蛋白抗体。

55. 发明授权

US07705153B2 Bipiperdine derivatives useful as CCR3 antagonists 失效
标题翻译：双哌啶衍生物可用作CCR3拮抗剂
公开(公告)号：US07705153B2
公开(公告)日：2010-04-27
申请号：US11049460
申请日：2005-02-02
申请人： Pauline C. Ting , Jianhua Cao , Youhao Dong , Eric J. Gilbert , Ying Huang , Joseph M. Kelly , Stuart McCombie , Neng-Yang Shih
发明人： Pauline C. Ting , Jianhua Cao , Youhao Dong , Eric J. Gilbert , Ying Huang , Joseph M. Kelly , Stuart McCombie , Neng-Yang Shih
IPC分类号： A61K31/4709 , A61K31/4725 , C07D215/14
CPC分类号： C07D401/14 , C07D211/18 , C07D211/58 , C07D401/04 , C07D471/04
摘要： The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.
摘要翻译：公开了使用式I的CCR3拮抗剂或其药学上可接受的盐治疗哮喘，以及式II的新型化合物，包含它们的药物组合物及其在治疗哮喘中的用途，其中R， Ra，X，Xa，R1，R2，R2a，R14，R14a，R16和n如说明书中所定义。

56. 发明申请

US20090312341A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT 有权
标题翻译：具有杂环取代基的循环胺BACE-1抑制剂
公开(公告)号：US20090312341A1
公开(公告)日：2009-12-17
申请号：US12490884
申请日：2009-06-24
申请人： Jared N. Cumming , Ying Huang , Guoqing Li , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Jianping Pan , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie
发明人： Jared N. Cumming , Ying Huang , Guoqing Li , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Jianping Pan , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie
IPC分类号： A61K31/496 , C12N9/99 , A61P25/28
CPC分类号： C04B35/632 , C07D207/277 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要： Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is X is —O—, —C(R14)2— or —N(R)—; Z is —C(R14)2— or —N(R)—; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR35, —N(R24) (R25) or —SR35; R41 is alkyl, cycloalkyl, —SO2(alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I.Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.
摘要翻译：公开了下式的新化合物或其药学上可接受的盐或溶剂合物，其中R 1是X是-O - ， - C（R 14）2 - 或-N（R） - ; Z是-C（R 14）2 - 或-N（R） - ; t为0,1,2或3; 每个R和R 2独立地为H，烷基，环烷基，环烷基烷基，芳基，杂芳基，杂环烷基，芳基烷基，杂芳基烷基，杂环烷基烷基，烯基或炔基; 每个R 14是H，烷基，烯基，炔基，卤素，-CN，卤代烷基，环烷基，环烷基烷基，芳基，杂芳基，杂环烷基，芳基烷基，杂芳基烷基，杂环烷基烷基，-OR 35，-N（R 24）（R 25）或-SR 35; R41是烷基，环烷基，-SO2（烷基），-C（O） - 烷基，-C（O） - 环烷基或 - 烷基-NH-C（O）CH3; 其余变量如本说明书中所定义。还公开了包含式I化合物的药物组合物和用式I化合物治疗认知障碍或神经变性疾病的方法。还公开了药物组合物和治疗方法，其包含式I化合物与用于治疗认知或神经变性的其它药剂疾病

57. 发明申请

US20090228867A1 Methods for Configuring Software Package 有权
标题翻译：配置软件包的方法
公开(公告)号：US20090228867A1
公开(公告)日：2009-09-10
申请号：US12042529
申请日：2008-03-05
申请人： Tirthankar Bandyopadhyay , Kumar Bhaskaran , Rajesh Chopra , Christina Derra (Schmidt) , Shiwa S. Fu , Ying Huang , Stephen K. Kibby , Santhosh Kumaran , Igor A. Naumov , Thomas D. Rosinski , Gerhard Sigl
发明人： Tirthankar Bandyopadhyay , Kumar Bhaskaran , Rajesh Chopra , Christina Derra (Schmidt) , Shiwa S. Fu , Ying Huang , Stephen K. Kibby , Santhosh Kumaran , Igor A. Naumov , Thomas D. Rosinski , Gerhard Sigl
IPC分类号： G06F9/44
CPC分类号： G06F8/71
摘要： A method for configuring a software package for an enterprise includes gathering desired To-be configuration requirements for a software package through at least one questionnaire; gathering current As-is raw data for the enterprise; displaying the To-Be configuration requirements and As-is raw data; comparing the To-Be configuration requirements and As-is raw data; selecting final To-Be configuration requirements; and generating and executing configuration code for the software package to pre-configure the software package with the final To-Be configuration requirements.
摘要翻译：用于配置企业的软件包的方法包括通过至少一个问卷收集对软件包的期望的To-be配置要求; 收集当前企业的原始数据; 显示To-Be配置要求和原始数据; 比较To-Be配置要求和原始数据; 选择最终的To-Be配置要求; 以及生成并执行软件包的配置代码以预配置具有最终To-Be配置要求的软件包。

58. 发明申请

US20090031204A1 Stakeholder Matrix 失效
标题翻译：利益相关方矩阵
公开(公告)号：US20090031204A1
公开(公告)日：2009-01-29
申请号：US11781605
申请日：2007-07-23
申请人： Ying Huang , Jim Laredo , Markus Gero Stolze , Piyawadee Sukaviriya , Brian White , Kuo Zhang
发明人： Ying Huang , Jim Laredo , Markus Gero Stolze , Piyawadee Sukaviriya , Brian White , Kuo Zhang
IPC分类号： G06F17/30 , G06F3/14 , G06F7/10
CPC分类号： G06Q10/06
摘要： A system implementing a situation-oriented directory for retrieving a stakeholder identification includes a memory storing a relational database corresponding to the situation-oriented directory including a plurality of attribute-value combinations and a plurality of stakeholder identifications, wherein the plurality of attribute-value combinations are mapped to the plurality of stakeholder identifications such that for each attribute-value combination exactly one stakeholder is mapped, and a processor in communication with the memory for receiving a query and retrieving the stakeholder identification from among the plurality of stakeholder identifications based on the attribute-value combinations.
摘要翻译：实现用于检索利益相关者识别的面向情况的目录的系统包括存储与所述面向目标的目录相对应的关系数据库的存储器，所述目录包括多个属性值组合和多个利益相关者标识，其中所述多个属性值组合映射到多个利益相关者标识，使得对于每个属性值组合恰好一个利益相关者被映射，以及处理器，与存储器通信，用于接收查询，并且基于该属性从多个利益相关者标识中检索利益相关者标识值组合。

59. 发明授权

US07408066B2 Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists 失效
标题翻译：碳链取代的哌啶及其衍生物可用作组胺H3拮抗剂
公开(公告)号：US07408066B2
公开(公告)日：2008-08-05
申请号：US11455873
申请日：2006-06-19
申请人： Robert G. Aslanian , Michael Y. Berlin , Ying Huang , Kevin D. McCormick , Mwangi W. Mutahi , Neng-Yang Shih , Pauline C. Ting , Wing C. Tom , Junying Zheng
发明人： Robert G. Aslanian , Michael Y. Berlin , Ying Huang , Kevin D. McCormick , Mwangi W. Mutahi , Neng-Yang Shih , Pauline C. Ting , Wing C. Tom , Junying Zheng
IPC分类号： C07D401/04 , C07D401/14 , A61K31/495
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14
摘要： Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH2)q—, —C(═NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.
摘要翻译：公开了下式的化合物或其药学上可接受的盐，其中：M 1和M 3是CH或N; M 2是CH，CF或N; Y是-C（-O） - ， - C（-S） - ， - （CH 2 CH 2）q - ， - C（-NOR 7） / SO 2 - ） - 或-SO 2 1-2。 Z是键或任选取代的亚烷基或亚烯基; R 1是H，烷基，烯基或任选取代的环烷基，芳基，杂芳基，杂环烷基或下式的基团：其中环A是单杂芳基环; R 2是任选取代的烷基，烯基，芳基，杂芳基，环烷基或杂环烷基; 剩余的变量如规范中所定义; 使用所述化合物单独或与其它试剂组合治疗过敏引起的气道反应，充血，肥胖，代谢综合征非酒精性脂肪性肝病，肝脂肪变性，非酒精性脂肪性肝炎，肝硬化，肝细胞癌或认知缺陷障碍的组合物和方法。

60. 发明授权

US07366706B2 Method and apparatus for solution-template based deployment and management of an integration solution 有权
标题翻译：用于基于解决方案模板的部署和管理集成解决方案的方法和设备
公开(公告)号：US07366706B2
公开(公告)日：2008-04-29
申请号：US10994248
申请日：2004-11-23
申请人： Hung-yang (Henry) Chang , Ying Huang , Jim Alain Laredo , Jeaha Yang , Ray Ming Yeh
发明人： Hung-yang (Henry) Chang , Ying Huang , Jim Alain Laredo , Jeaha Yang , Ray Ming Yeh
IPC分类号： G06F17/00 , G06N5/00
CPC分类号： G06F9/50
摘要： A method for automating the deployment and lifecycle management of an integration solution by using a deployment solution template to gather deployment information, where the integration solution combines components developed separately or on different platforms. The deployment information gathered includes the computing environment topology into which the integration solution is being deployed, as well as the resource requirements and non-functional requirements of the integration solution and its components. The method provides computer implemented models for analyzing the gathered deployment information, and identifying and optimizing deployment options. Choices for selection among identified and optimized options based on non-functional requirements of the integration solution may be displayed to a user of the deployment method. The deployment template may be customized to modify the information being gathered in view of the analysis provided by the models, and in order to use the template and models in subsequent deployments and for the management of the integration solution.
摘要翻译：一种通过使用部署解决方案模板来收集部署信息来自动化集成解决方案的部署和生命周期管理的方法，集成解决方案集成了单独开发或在不同平台上开发的组件。收集的部署信息包括部署集成解决方案的计算环境拓扑，以及集成解决方案及其组件的资源需求和非功能需求。该方法提供计算机实现的模型，用于分析收集的部署信息，以及识别和优化部署选项。可以向部署方法的用户显示基于集成解决方案的非功能需求的在已识别和优化的选项中进行选择的选择。可以定制部署模板，以便根据模型提供的分析修改正在收集的信息，以及在后续部署中使用模板和模型以及管理集成解决方案。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式